Phase I Trial of Bevacizumab and Temsirolimus in Combination With 1) Carboplatin, 2) Paclitaxel, 3) Sorafenib for the Treatment of Advanced Cancer

StatusActive, Not Recruiting
PhasePhase 1
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 2 years later Apr 30, 2026 → Apr 30, 2028
See other at-risk trials from M.D. Anderson Cancer Center

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary and study completion pushed from Apr 30, 2026 to Apr 30, 2028 Show 4 more changesShow less
    • Eligibility criteria expanded, about 28 words
    • Secondary endpoints: details revised at 3 of 3 entries
    • Study description expanded, about 7 words
    • Publications: details revised at 1 of 1 entry
  2. 4 versions Re-verified since Nov 26, 2024, no change to tracked fieldsv34-v37
  3. Primary and study completion dates: Apr 30, 2024 to Apr 30, 2026v33
  4. Re-verified, no change to tracked fieldsv32
  5. Start date: Aug 2010 to Aug 19, 2010v31
Show 29 earlier versionsHide 29 earlier versions
  1. Primary and study completion dates: Dec 2022 to Apr 30, 2024v30
  2. Re-verified, no change to tracked fieldsv29
  3. Primary and study completion dates: Dec 2021 to Dec 2022v28
  4. Primary and study completion dates: Aug 2019 to Dec 2021v27
  5. Re-verified, no change to tracked fieldsv26
  6. Primary completion date: Aug 2018 to Aug 2019
    • Study completion date: Aug 2019
    v25
  7. Re-verified, no change to tracked fieldsv24
  8. Trial status: Recruiting to Active, Not Recruiting
    • Secondary endpoints expanded, about 36 words
    • Site details revised
    v23
  9. Primary completion date: Aug 2017 to Aug 2018v22
  10. Study title expanded, about 16 wordsv21
  11. Study description shortened, about 5 wordsv20
  12. Primary completion date: Aug 2016 to Aug 2017
    • Study description shortened, about 19 words
    v19
  13. 2 versions Re-verified since Sep 25, 2014, no change to tracked fieldsv17-v18
  14. Primary completion date: Aug 2015 to Aug 2016
    • Study site revised
    v16
  15. Study description expanded, about 360 wordsv15
  16. 3 versions Re-verified since May 8, 2013, no change to tracked fieldsv12-v14
  17. Eligibility criteria expanded, about 1 wordv11
  18. 4 versions Re-verified since Apr 26, 2012, no change to tracked fieldsv7-v10
  19. Enrollment target: 230 to 278
    • Study description expanded, about 73 words
    v6
  20. 2 versions Re-verified since Aug 1, 2011, no change to tracked fieldsv4-v5
  21. Eligibility criteria expanded, about 12 words
    • Study description shortened, about 6 words
    • Site contact updated
    v3
  22. Re-verified, no change to tracked fieldsv2
  1. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The goal of this clinical research study is to find the highest tolerable dose of the combination of bevacizumab (Avastin) and temsirolimus (Torisel) that can be given with 1 of 3 other study drugs --carboplatin (Paraplatin), paclitaxel (Taxol), or sorafenib (Nexavar). The safety of these drug combinations will also be studied.
Trial Details
NCT Number NCT01187199
Lead Sponsor M.D. Anderson Cancer Center
Conditions
(from sponsor)		 Advanced Cancer
Related terms Neoplasm Metastasis
Enrollment 278 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov